Sarcopenia on preoperative chest computed tomography predicts cancer-specific and all-cause mortality following pneumonectomy for lung cancer: A multicenter analysis

Fabian M. Troschel1,2 | Qianna Jin3,4,5,6 | Florian Eichhorn5,7 | Thomas Muley5,7 | Till D. Best2,8 | Konstantin S. Leppelmann2 | Chi-Fu Jeffrey Yang9 | Amelie S. Troschel2 | Hauke Winter5,7 | Claus P. Heußel3,4,5 | Henning A. Gaisser9 | Florian J. Fintelmann2

1Department of Radiation Oncology, Münster University Hospital, Münster, Germany
2Department of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, Boston, Massachusetts, USA
3Department of Diagnostic and Interventional Radiology with Nuclear Medicine, Thoraxklinik Heidelberg at Heidelberg University Hospital, Heidelberg, Germany
4Department of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany
5Translational Lung Research Centre (TLRC) Heidelberg, German Centre for Lung Research, Heidelberg, Germany
6Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7Department of Surgery, Thoraxklinik, Heidelberg University Hospital, Heidelberg, Germany
8Department of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin Institute of Health, Berlin, Germany
9Department of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, Massachusetts

Abstract

Background: Mortality risk prediction in patients undergoing pneumonectomy for non-small cell lung cancer (NSCLC) remains imperfect. Here, we aimed to assess whether sarcopenia on routine chest computed tomography (CT) independently predicts worse cancer-specific (CSS) and overall survival (OS) following pneumonectomy for NSCLC.

Methods: We included consecutive adults undergoing standard or carinal pneumonectomy for NSCLC at Massachusetts General Hospital and Heidelberg University from 2010 to 2018. We measured muscle cross-sectional area (CSA) on CT at thoracic vertebral levels T8, T10, and T12 within 90 days prior to surgery. Sarcopenia was defined as T10 muscle CSA less than two standard deviations below the mean in healthy controls. We adjusted time-to-event analyses for age, body mass index, Charlson Comorbidity Index, forced expiratory volume in 1 second in % predicted, induction therapy, sex, smoking status, tumor stage, side of pneumonectomy, and institution.

Results: Three hundred and sixty-seven patients (67.4% male, median age 62 years, 16.9% early-stage) underwent predominantly standard pneumonectomy (89.6%) for stage IIIA NSCLC (45.5%) and squamous cell histology (58%). Sarcopenia was present in 104 of 367 patients (28.3%). Ninety-day all-cause mortality was 7.1% (26/367). After a median follow-up of 20.5 months (IQR, 9.2–46.9), 183 of 367 patients (49.9%) had died. One hundred and thirty-three (72.7%) of these deaths were due to lung cancer. Sarcopenia was associated with shorter CSS (HR 1.7, p = 0.008) and OS (HR 1.7, p = 0.003).
1 | INTRODUCTION

Pneumonectomy in patients with non-small cell lung cancer (NSCLC) is associated with high postoperative and long-term mortality with reported averages of 5%–12% at 90 days\(^1\)\(^-\)\(^3\) and 60%–70% at 5 years\(^1\)\(^,\)\(^4\). Important known risk factors for mortality following pneumonectomy include clinical tumor stage\(^5\), preoperative pulmonary function testing\(^6\), comorbidities\(^2\), and male sex\(^5\). However, mortality risk prediction remains imperfect\(^1\)\(^,\)\(^7\)\(^,\)\(^8\).

Muscle cross-sectional area (CSA) on CT scans obtained for routine care may diagnose sarcopenia\(^9\)\(^,\)\(^10\). Current evidence supporting low muscle mass as a predictor of early death after lung resection is predominantly based on single-center cohorts of patients who underwent lobectomy, a less mortal, and morbid procedure compared to pneumonectomy\(^11\). An association of OS after pneumonectomy with psoas muscle mass at the level of the third lumbar vertebra (L3) and thoracic muscle mass has been reported in two single-center cohorts of about 150 patients each\(^12\)\(^,\)\(^13\). However, sarcopenia on chest CT based on externally validated cut-off values and the link with cancer-specific survival (CSS) have not been previously investigated in the context of pneumonectomy for NSCLC.

To confirm whether preoperative sarcopenia on chest CT predicts mortality following pneumonectomy in patients with lung cancer, we developed this bi-institutional transatlantic cohort study in January 2019 with the a priori hypothesis that sarcopenia on preoperative chest CT is an independent risk factor for cancer-specific and overall survival following pneumonectomy for NSCLC.

2 | METHODS

This retrospective study was approved by the Institutional Review Boards at Massachusetts General Hospital (MGH; 2018P000301) and Heidelberg University Thoraxklinik (HDB; S-295/2020). The need for informed consent was waived.

\section*{2.1 | Inclusion and exclusion criteria}

Consecutive adult patients undergoing standard and carinal pneumonectomy for non-small cell lung cancer at the two institutions between January 1, 2010, and December 31, 2018, were included. completion pneumonectomy, pleuropneumonectomy, and pneumonectomy with palliative intent were excluded.

Patients were identified using prospectively maintained registries, the institutional sample of the Society of Thoracic Surgeons (STS) General Thoracic Surgery Database (GTSD) at the MGH and the institutional cancer registry at HDB. Three exclusion criteria were applied (Figure 1): Patients without available chest CT scan within 90 days prior to pneumonectomy\(^14\)\(^,\)\(^15\) artifacts precluding

\message{Conclusions: This transatlantic multicenter study confirms that sarcopenia on preoperative chest CT is an independent risk factor for CSS and OS following pneumonectomy for NSCLC.

\textbf{KEYWORDS}

non-small cell lung cancer, sarcopenia, survival

\message{Lay summary}

Removal of an entire lung (pneumonectomy) is a surgical procedure with high mortality risk. Thus, it is crucial to provide each patient with an individualized pre-operative risk assessment. This transatlantic, bi-institutional cohort study aimed to assess whether low muscle (sarcopenia) on chest computed tomography (CT) scans obtained for routine preoperative evaluation can identify patients with lung cancer at increased risk of death following pneumonectomy. Among 367 patients, we found that sarcopenia is an independent risk factor for death and that consideration of sarcopenia in addition to established predictors significantly improves the accuracy of cancer-specific and overall survival estimation.
assessments of sarcopenia at the T10 thoracic vertebral body, and incomplete clinical data.

### 2.2 | Muscle measurements

Trained analysts (one radiation oncologist, one radiologist) blinded to outcomes independently quantified total muscle CSA on an axial image at the level of the T8, T10, and T12 thoracic vertebral bodies under the supervision of board-certified thoracic radiologists (F.J.F., C.P.H.). Analysts used semi-automated threshold-based segmentation (−29 to +150 Hounsfield units) as illustrated in Figure 2 and previously described. Analysts used OsiriX Lite software (version 11.0.3, Pixmeo SARL, Bernex, Switzerland) at MGH and the Syngo Volume tool (Siemens Healthineers) at HDB. Twenty-five randomly selected subjects were assessed with both software packages to determine inter-software agreement. Two additional sets of 25 randomly selected subjects (one set per institution) were compared with the same software to determine inter-analyst agreement.

### 2.3 | Data collection, outcomes, and explanatory variable

Clinical data abstracted from prospective registries included patient demographics, co-morbidities, tumor, and treatment details, as well as postoperative adverse events. Induction therapy was defined as pre-operative chemotherapy, radiotherapy, or chemo-radiotherapy. Pathologic tumor stage was uniformly classified according to the eighth edition of the tumor, node, and metastasis (TNM) classification for lung cancer.

The primary outcome was cancer-specific survival and the secondary outcome was overall survival. Vital status and date of the last follow-up were determined using the institutional registry, electronic medical record, and online obituaries, as previously described. Survival time was calculated in months from the date of resection. Patients without recorded death were censored at last contact as of 12/31/2019. The cause of death was categorized as cancer-specific, non-cancer-specific or unknown by each institutional registry.

The explanatory variable was sarcopenia defined as muscle CSA at T10 two standard deviations below the mean of a healthy reference group reported by Derstine et al. We also explored associations with continuous muscle CSA (10 cm² steps) at T8, T10, and T12.

### 2.4 | Statistical analysis

Patient characteristics are presented using descriptive statistics including mean and standard deviation, or median and interquartile range. Differences in patient characteristics (sarcopenic vs. non-sarcopenic; MGH vs. HDB) were assessed using t-tests, χ², and Mann–Whitney U-tests. Correlations between muscle measurements at different levels were assessed with Pearson correlations. Univariable relationships between sarcopenia, cancer-specific survival, and overall survival were estimated using the Kaplan–Meier method and assessed for statistical significance with the log-rank
test. For multivariable analyses, Cox proportional hazard models were developed using a priori defined variables previously associated with survival following pneumonectomy for lung cancer: Age, body mass index (BMI), comorbidities (summarized using the Charlson Comorbidity Index [CCI], as previously validated in lung cancer resections), forced expiratory volume in 1 second in % predicted (FEV1% pred), induction therapy, sex, smoking status, tumor stage, and side of pneumonectomy. Institution (MGH or HDB) was added as a covariable. Analyses were performed using sarcopenia (primary) and muscle at each level as a continuous variable (secondary).

The likelihood-ratio test was used to assess whether the addition of sarcopenia or muscle improved model fit comparing the full models to restricted models without sarcopenia or muscle. Inter-software and inter-analyst agreement were assessed using intraclass correlation coefficients. All analyses were performed using STATA (version 13.0, StataCorp). A type-1 error rate of 5% was assumed for all confidence intervals and hypothesis tests.

3 | RESULTS
3.1 | Patient characteristics

Overall, 367 of 443 consecutive screened patients (82.8%) were included. Patient, tumor, and treatment details are summarized in Table 1.

During the study period, the pneumonectomy rate compared to all resections for lung cancer was 3.8% at MGH and 11.3% at HDB. Differences in patient selection between the two institutions are reflected in a greater proportion of induction therapy and higher BMI at MGH, while HDB had a greater frequency of stage III disease and active smokers (Table S1). The indication for pneumonectomy in tumors pathologically staged as Tx, stage I or stage IVA is detailed in Table S2.

Mortality was 4.6% (17/367) at 30 days and 7.1% (26/367) at 90 days, without significant differences between the institutions. After a median follow-up of 20.5 months, 183 of 367 patients (49.9%) had died. Of these deaths, 133 (72.7%) were classified as tumor-specific, while 30 patients (16.4%) died of non-cancer-related causes (Table S3). The cause was unknown in 20 of 183 deaths (10.9%). Long-term survival was similar between the institutions. Post-surgical complications during the hospital stay are detailed in Table S4.

3.2 | Muscle measurements

Criteria for sarcopenia were met by 104 of 367 (28.3%) patients. Patients with sarcopenia were more likely to be male, older, and have a lower BMI, lower preoperative FEV1, and more comorbidities (Table 1). The median muscle area was highest at T8 and lowest at T10, both with and without stratifying by sex (Table S5). The median muscle area was more than 50% higher in males compared to females ($p < 0.001$; Figure 2).

Compared to T10, our reference for study inclusion, muscle measurements were less frequently available at T8 (98.1%) compared to T12 (99.2%) due to incomplete visualization with a small field of view in seven patients at T8 and in three patients at T12. Muscle at all levels demonstrated moderate to strong correlation (Figure S1). Inter-software and inter-analyst agreement were excellent (Table S6).

3.3 | Univariable analyses for sarcopenia as a binary explanatory variable

In univariable analyses, survival was shorter in sarcopenic patients compared to non-sarcopenic patients (Figure 3). Median CSS was 29.4 months in sarcopenic and 78.9 months in non-sarcopenic patients ($p = 0.006$). Median OS was 17.7 months in sarcopenic and 46.5 months in non-sarcopenic patients ($p = 0.0006$).

3.4 | Multivariable analyses for sarcopenia as a binary explanatory variable

In multivariable Cox proportional hazard regression models adjusted for parameters known to be associated with survival, sarcopenia was independently associated with cancer-specific survival (hazard ratio [HR] $1.74$, $p = 0.008$) and overall survival (HR $1.68$, $p = 0.003$; Table 2 for CSS, Table S7 for OS).,2,5,13,19–22

3.5 | Predictive capability

Likelihood ratio tests were performed to compare cancer-specific and overall survival in models with and without muscle measurements, using sarcopenia as a categorical variable or muscle area as a continuous variable for each level, T8, T10, and T12, separately. Models that included muscle measurements demonstrated a significantly better fit than models excluding muscle (Table 2). The signal was strongest at T8, less strong at T10, while muscle measurements at T12 were not associated with either cancer-specific or overall survival. These findings indicate that muscle area at T8 and T10, when combined with known predictors of survival, improves the prediction of cancer-specific and overall survival.
# Table 1

Patient characteristics, stratified by presence of sarcopenia. Median and interquartile range, mean and standard deviation or number, and percentage are given, as appropriate.

| General patient characteristics | All (n = 367) | Sarcopenic (n = 104) | Non-sarcopenic (n = 263) | p value |
|---------------------------------|--------------|----------------------|--------------------------|---------|
| Age, years, median (range)      | 62.2 (56.0–68.8) | 64 (58.9–71.6) | 60.7 (54.2–67.4) | **<0.001**<sup>a</sup> |
| Body mass index, kg/m², median (range) | 25.4 (22.9–28.5) | 24.4 (22.2–26.3) | 26.3 (23.1–29.6) | **<0.001**<sup>a</sup> |
| Height, cm, mean (standard deviation) | 171.4 (8.9) | 172 (167.3–177.9) | 171 (165–177) | 0.29<sup>c</sup> |
| Weight, kg, median (range)      | 75 (65.4–87) | 71 (65–80.2) | 76 (66–90) | **0.003**<sup>b</sup> |
| Male, n (%)                     | 247 (67.3) | 86 (82.7) | 161 (61.2) | **<0.001**<sup>b</sup> |
| FEV1% pred<sup>d</sup>, %, mean (standard deviation) | 77.5 (19.2) | 73.6 (18.3) | 79.1 (19.4) | **0.014**<sup>c</sup> |

| Patient comorbidities           |               |                      |                          |         |
|---------------------------------|---------------|----------------------|--------------------------|---------|
| Charlson Comorbidity Index, median (range) | 4 (3–5) | 4 (4–5.5) | 4 (3–5) | **0.001**<sup>a</sup> |
| Prior myocardial infarction, n (%) | 31 (8.4) | 7 (6.7) | 24 (9.1) | 0.46<sup>b</sup> |
| Congestive heart failure, n (%)  | 0 (0)         | 0 (0)                | 0 (0)                    | 1<sup>b</sup> |
| Chronic obstructive pulmonary disease, n (%) | 69 (18.8) | 21 (20.2) | 48 (18.3) | 0.67<sup>b</sup> |
| Diabetes mellitus, n (%)         | 24 (6.5)      | 8 (7.7)              | 16 (6.1)                 | 0.57<sup>b</sup> |
| Smoking status, n (%)            |               |                      |                          | 0.09<sup>b</sup> |
| Never                            | 36 (9.8)      | 6 (5.8)              | 30 (11.4)                |         |
| Former                           | 222 (60.5)    | 60 (57.7)            | 162 (61.6)               |         |
| Current                          | 109 (29.7)    | 38 (36.5)            | 71 (27.0)                |         |

| Tumor characteristics & treatment details |               |                      |                          |         |
|-------------------------------------------|---------------|----------------------|--------------------------|---------|
| Stage, n (%)                               |               |                      |                          | 0.76<sup>b</sup> |
| I                                         | 13 (3.5)      | 5 (4.8)              | 8 (3.0)                  |         |
| II                                        | 51 (13.9)     | 14 (13.4)            | 37 (14.1)                |         |
| IIIA                                       | 167 (45.5)    | 52 (50.0)            | 115 (43.7)               |         |
| IIIB                                       | 111 (30.3)    | 26 (25.0)            | 85 (32.3)                |         |
| IVA                                        | 18 (4.9)      | 5 (4.8)              | 13 (4.9)                 |         |
| Tx                                         | 7 (1.9)       | 2 (1.9)              | 5 (1.9)                  |         |
| Histology, n (%)                           |               |                      |                          | 0.1<sup>b</sup> |
| Squamous cell                              | 212 (57.8)    | 70 (67.3)            | 142 (54.0)               |         |
| Adenocarcinoma                             | 120 (32.7)    | 29 (27.9)            | 91 (34.6)                |         |
| Large cell carcinoma                       | 9 (2.5)       | 0 (0)                | 9 (3.4)                  |         |
| Carcinoid                                  | 8 (2.2)       | 0 (0)                | 5 (1.9)                  |         |
| Adenosquamous carcinoma                    | 5 (1.4)       | 3 (2.9)              | 5 (1.9)                  |         |
| Neuroendocrine carcinoma                   | 4 (1.1)       | 0 (0)                | 4 (1.5)                  |         |
| Bronchial gland type carcinoma             | 3 (0.8)       | 0 (0)                | 3 (1.1)                  |         |
| Non-small cell lung cancer, not otherwise specified | 6 (1.6) | 2 (1.9) | 4 (1.5) |         |
| Type of pneumonectomy, n (%)               |               |                      |                          | 0.93<sup>b</sup> |
| Standard pneumonectomy                     | 329 (90.6)    | 93 (89.4)            | 236 (89.7)               |         |
| Carinal pneumonectomy                      | 38 (10.4)     | 11 (10.6)            | 27 (10.3)                |         |
| Side of pneumonectomy, n (%)               |               |                      |                          | 0.85<sup>b</sup> |
| Right                                      | 163 (44.4)    | 47 (45.2)            | 116 (44.1)               |         |
| Left                                       | 204 (55.6)    | 57 (54.8)            | 147 (55.9)               |         |
| Induction therapy, n (%)                   | 38 (10.4)     | 8 (7.7)              | 30 (11.4)                | 0.29<sup>b</sup> |

Significance of bold means p value < 0.05.

<sup>a</sup>Mann–Whitney U test.

<sup>b</sup>χ² test.

<sup>c</sup>t test.

<sup>d</sup>FEV1% pred, forced expiratory volume in 1 second, in % predicted.

*p*-values <0.05 are printed in bold numerics.
survival following pneumonectomy in patients with NSCLC.

4 | DISCUSSION

The present study analyzed surgical lung cancer cohorts from two tertiary care centers in North America and Europe to examine whether sarcopenia on routine preoperative chest CT predicts survival following pneumonectomy for NSCLC. Patients with sarcopenia based on the assessment of muscle mass at the level of the tenth thoracic vertebral body experienced significantly worse cancer-specific and overall survival following pneumonectomy. Both sarcopenia and muscle mass at levels T8 and T10 were independently associated with cancerspecific and overall survival in univariable and multivariable models. The likelihood-ratio test confirmed that the addition of thoracic muscle mass increases the predictive capability of established risk prediction models. These findings strongly suggest that muscle on chest CT scans obtained as part of preoperative evaluation can be harnessed to improve the prediction of death from lung cancer following pneumonectomy.

FIGURE 2 Representative example of muscle segmentation at three thoracic vertebral levels (left column) and distribution of cross-sectional muscle area of all patients (males, middle column; females, right column). Left column: Pixels identified as muscle (red) superimposed on axial computed tomography images at the level of the 8th (T8), 10th (T10), and 12th (T12) thoracic vertebral body in a 79-year-old male. Histograms with muscle cross-sectional area (in cm²) at each level for males (middle column) and females (right column).

FIGURE 3 Kaplan–Meier plot illustrates cancer-specific survival (A) and overall survival (B) following pneumonectomy for lung cancer in sarcopenic and non-sarcopenic patients. Sarcopenic patients experienced significantly shorter cancer-specific and overall survival when compared to non-sarcopenic patients ($p = 0.006$ for CSS, $p = 0.0006$ for OS).
TABLE 2  Multivariable Cox proportional hazard regression of cancer-specific survival after pneumonectomy for lung cancer. Disease stages are categorized as early (stages I, II), locally advanced (stage IIIA), and advanced (stage IIIB, IV)

| Sarcopenia (yes vs. no [reference]) | T8 (10 cm²) n = 360 | T10 (10 cm²) n = 367 | T12 (10 cm²) n = 364 |
|-------------------------------------|----------------------|----------------------|----------------------|
| **HR (CI)**                         | **p**                | **HR (CI)**          | **p**                | **HR (CI)**          | **p** |
| Muscle                              | 1.74 (1.16–2.60)     | 0.008                | 0.82 (0.73–0.91)     | <0.001               | 0.81 (0.70–0.93)     | 0.003 |
| Age, years                          | 0.98 (0.95–1.01)     | 0.22                 | 0.98 (0.95–1.01)     | 0.11                 | 0.98 (0.95–1.01)     | 0.14  |
| Body mass index, kg/m²              | 0.94 (0.90–0.99)     | 0.023                | 0.95 (0.90–0.99)     | 0.029                | 0.96 (0.91–1.02)     | 0.17  |
| Charlson Comorbidity Index          | 1.24 (1.01–1.53)     | 0.041                | 1.21 (0.99–1.50)     | 0.07                 | 1.25 (1.02–1.54)     | 0.034 |
| FEV1% pred¹, %                      | 1.00 (0.99–1.01)     | 0.48                 | 1.00 (1.00–1.01)     | 0.34                 | 1.00 (0.99–1.01)     | 0.50  |
| Induction therapy                   | 1.56 (0.83–2.92)     | 0.16                 | 1.57 (0.83–2.98)     | 0.17                 | 1.53 (0.82–2.88)     | 0.18  |
| **Sex**                             |                      |                      |                      |                      |                      |      |
| Male                                | Ref.                 |                      | Ref.                 |                      | Ref.                |      |
| Female                              | 0.75 (0.50–1.12)     | 0.16                 | 0.27 (0.15–0.50)     | <0.001               | 0.34 (0.19–0.61)     | <0.001 |
| **Smoking status**                  |                      |                      |                      |                      |                      |      |
| Never                               | 0.99 (0.57–1.73)     | 0.98                 | 0.95 (0.55–1.66)     | 0.87                 | 0.99 (0.57–1.72)     | 0.98  |
| Former                              | Ref.                 |                      | Ref.                 |                      | Ref.                |      |
| Current                             | 0.63 (0.41–0.97)     | 0.036                | 0.62 (0.40–0.97)     | 0.034                | 0.63 (0.41–0.98)     | 0.039 |
| **Stage**                           |                      |                      |                      |                      |                      |      |
| I & II                              | 0.34 (0.57–1.73)     | 0.004                | 0.34 (0.16–0.72)     | 0.005                | 0.37 (0.17–0.76)     | 0.007 |
| Tx                                  | 0.70 (0.18–2.68)     | 0.60                 | 0.56 (0.15–2.14)     | 0.39                 | 0.63 (0.16–2.40)     | 0.50  |
| IIIA                                | Ref.                 |                      | Ref.                 |                      | Ref.                |      |
| IIIB & IV                           | 1.55 (1.07–2.25)     | 0.021                | 1.49 (1.03–2.16)     | 0.036                | 1.55 (1.07–2.25)     | 0.021 |
| **Side of pneumonectomy**           |                      |                      |                      |                      |                      |      |
| Right                               | Ref.                 |                      | Ref.                 |                      | Ref.                |      |
| Left                                | 0.90 (0.63–1.28)     | 0.56                 | 0.89 (0.62–1.27)     | 0.52                 | 0.86 (0.61–1.22)     | 0.40  |
| **Institution**                     |                      |                      |                      |                      |                      |      |
| MGH⁶                                | Ref.                 |                      | Ref.                 |                      | Ref.                |      |
| HDB⁷                                | 1.12 (0.62–2.03)     | 0.70                 | 1.03 (0.57–1.88)     | 0.91                 | 1.06 (0.59–1.91)     | 0.85  |
| **Likelihood-ratio test**           |                      |                      |                      |                      |                      |      |
| Restricting muscle                  | 0.0093               | 0.0002               | 0.0031               | 0.96                 |

Significance of bold means p value < 0.05.
¹FEV1% pred, forced expiratory volume in 1 second, in % predicted.
⁶MGH, Massachusetts General Hospital.
⁷HDB, Heidelberg University Thoraxklinik.

p-values <0.05 are printed in bold numerics.
The current study is the first to demonstrate a link between cancer-specific survival and thoracic muscle mass. We prefer muscle assessment on preoperative chest CT scans to other radiographic examinations and bioimpedance because segmentation readily quantifies regional truncal muscle mass relevant to respiration and expectoration; guidelines already recommend chest CT, thereby avoiding additional tests and radiation exposure.11,14,23

Our findings expand the evidence relating muscle mass to cancer-specific survival. The muscle area on abdominal CT at the level of the third lumbar vertebral body is an established predictor of cancer-specific survival following resection of infra-diaphragmatic malignancies.24–28 Psoas muscle area on preoperative abdominal CT has also been linked to OS in patients with lung cancer in a single-center study.12 Our own single-center study provided preliminary data suggesting that muscle area on chest CT at the level of T8 was also associated with OS following pneumonectomy but relied on a cohort-specific cutoff value.13 A bi-institutional study investigating overall mortality following various anatomic and non-anatomic resections for lung cancer failed to uncover direct correlations between muscle area and survival and relied on a “morphometric index” with a cohort-specific cutoff value.29 The investigators included anatomic lung resections equal or greater than segmentectomy and we suspect their pneumonectomy rate was low. Without reference to healthy controls, none of these studies firmly establish sarcopenia as a risk factor. The present study defines sarcopenia on chest CT through comparison with an independent cohort of healthy kidney donors, thereby avoiding the unreliability of cohort-specific reference values.9

We included patients from two institutions in North America and Europe to achieve diversity in patient selection, radiographic technique, muscle assessment software, operative technique, and postoperative clinical management. This study, therefore, tested the association between muscle area and survival under various conditions and for the most extensive type of lung resection with the greatest perioperative risk. We excluded resections extending beyond the parietal pleura as well as completion pneumonectomies and pneumonectomy with a palliative intent given the different risk profiles of these resections.30,31 Variations in patient selection criteria between the institutions imply that conclusions from this study may be widely applicable.

Our comprehensive pre-specified model considers all established risk factors for mortality following pneumonectomy in patients with lung cancer, as well as the side of pneumonectomy21 and an institutional variable. We included the CCI to account for comorbidities as previously validated.2,19 As expected, we found that higher tumor stage5 and male sex5 were negatively associated with survival. Smoking status,20 comorbidities,2 and induction therapy32—which requires careful patient selection in the neoadjuvant setting33—showed trends toward worse survival. Similar to prior studies, pulmonary function tests showed no significant effect.13 As previously demonstrated, age was not associated with survival, highlighting that mortality risk is not so much defined by chronologic, but morphologic age.16,34–36

The choice of analyzed thoracic vertebral levels in this study was informed by prior reports and our own institutional experience.13,16,23 While we observed strong inter-level correlations, muscle mass at the T8 level was the best predictor of survival, while muscle mass at T10 was inferior to T8 but still significant. We were surprised to find muscle mass at T12 showed no association with survival while muscle mass at T10 is most closely correlated with muscle mass at the commonly referenced L3 level.9 We suspect that shoulder muscles supporting upper extremity function which are visualized at T8 and to a lesser extent at T10, contribute to the ability of muscle mass at these levels to predict survival.23 We thus hypothesize that the combination of respiratory and shoulder musculature may be more helpful in survival prediction following pneumonectomy in patients with lung cancer than respiratory muscles alone.

There are some notable limitations to this study. First, the retrospective design precluded preoperative assessment of muscle strength and function (which some studies recommend37) and resulted in some exclusions due to missing data. However, the exclusion rate is low compared to other lung cancer body composition studies and we believe that our sample is representative.13,14 Second, we had to retrospectively convert some TNM stages from the seventh to the eighth edition to achieve uniformity. Third, we chose to rely on pathologic instead of clinical staging given that pathologic staging was universally available and is strongly correlated with clinical stage.28 Last, we were unable to include race and ethnicity despite evidence that it affects body composition39 and outcomes in patients with lung cancer40 because these parameters are not commonly collected in Germany.

In conclusion, this transatlantic bi-institutional study confirms sarcopenia on preoperative chest CT as an independent binary risk factor for both cancer-specific and overall survival following pneumonectomy for lung cancer. Muscle mass as a continuous variable at vertebral levels T8 and T10 is also independently associated with survival following pneumonectomy for lung cancer. In the future, muscle mass on chest CT scans obtained as part of guideline-concordant preoperative evaluation could be harnessed to improve mortality risk prediction in patients undergoing pneumonectomy for lung cancer.
CONFLICTS OF INTEREST
F.J.F. was supported by the American Roentgen Ray Society Scholarship during the study period and has a related patent pending. T.M. and C.P.H. hold patents not related to this study. The other authors do not report relevant conflicts of interest.

AUTHOR CONTRIBUTIONS
Fabian M. Troschel: Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - original draft. Qianna Jin: Data curation, Investigation, Methodology, Writing - review & editing. Florian Eichhorn: Investigation, Methodology, Writing - review & editing. Thomas Muley: Data curation, Investigation, Methodology, Writing - review & editing. Till D. Best: Data curation, Investigation, Validation, Writing - review & editing. Konstantin S. Leppelmann: Data curation, Investigation, Validation, Writing - review & editing. Amelie S. Troschel: Data curation, Investigation, Writing - review & editing. Henning A. Gaißert: Investigation, Methodology, Supervision, Writing - review & editing. Florian J. Fintelmann: Conceptualization, Data curation, Investigation, Methodology, Project administration, Supervision, Writing - review & editing.

DATA AVAILABILITY STATEMENT
Research data (including CT scans) cannot be shared for ethical reasons given the scarcity of the investigated procedure and, thus, the identifiability of individual patients.

ORCID
Fabian M. Troschel ḏ https://orcid.org/0000-0001-5066-6650

REFERENCES
1. Jones GD, Caso R, Tan KS, et al. Propensity-matched analysis demonstrates long-term risk of respiratory and cardiac mortality after pneumonectomy compared with lobectomy for lung cancer. Ann Surg. 2020; Publish Ah(Xx):1–7. https://doi.org/10.1097/SLA.0000000000004065
2. Green A, Hauge J, Iachina M, Jakobsen E. The mortality after surgery in primary lung cancer: results from the Danish Lung Cancer Registry. Eur J Cardio-thoracic Surg. 2016;49(2):589-594. https://doi.org/10.1093/ejcts/ezy107
3. Powell HA, Tata LJ, Baldwin DR, Stanley RA, Khakwani A, Hubbard RB. Early mortality after surgical resection for lung cancer: an analysis of the English National Lung cancer audit. Thorax. 2013;68(9):826-834. https://doi.org/10.1136/thoraxjnl-2012-203123
4. Ludwig C, Stoeber E, Olschewski M, Hasse J. Comparison of morbidity, 30-day mortality, and long-term survival after pneumonectomy and sleeve lobectomy for non-small cell lung carcinoma. Ann Thorac Surg. 2005;79(3):968-973. https://doi.org/10.1016/j.thorsur.2004.08.062
5. Fernandez FG, Kosinski AS, Burfeind W, et al. STS lung cancer resection risk model: higher quality data and superior outcomes. Ann Thorac Surg. 2016;102(2):370-377. https://doi.org/10.1016/j.thorsur.2016.02.098
6. Ferguson MK, Watson S, Johnson E, Vigneswaran WT. Predicted postoperative lung function is associated with all-cause long-term mortality after major lung resection for cancer. Eur J Cardio-thoracic Surg. 2014;45(4):660-664. https://doi.org/10.1093/ejcts/ezt462
7. Dhanasopon AP, Salazar MC, Hoag JR, et al. Fate of pneumonectomy patients variably captured by non-small cell lung cancer staging system. Ann Thorac Surg. 2017;104(6):1829-1836. https://doi.org/10.1016/j.athoracsur.2017.06.073
8. Ha D, Mazzone PJ, Ries AL, Malhotra A, Fuster M. The Utility of exercise testing in patients with lung cancer. J Thorac Oncol. 2016;11(9):1397-1410. https://doi.org/10.1016/j.jtho.2016.04.021
9. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep. 2018;8(1):1-8. https://doi.org/10.1038/s41598-018-29825-5
10. Psutka SP. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer. 2020;126(17):3912–3915. https://doi.org/10.1002/cncr.32993
11. Sun C, Anraku M, Karasaki T, et al. Low truncal muscle area on chest computed tomography: a poor prognostic factor for the cure of early-stage non-small-cell lung cancer. Eur J Cardio-thoracic Surg. 2019;55(3):414-420. https://doi.org/10.1093/ejcts/ezy324
12. Hervochon R, Bobbio A, Guinet C, et al. Body mass index and total psoas area affect outcomes in patients undergoing pneumonectomy for cancer. Ann Thorac Surg. 2017;103(1):287-295. https://doi.org/10.1016/j.athoracsur.2016.06.077
13. Troschel FM, Kuklinski MW, Knoll SJ, et al. Preoperative thoracic muscle area on computed tomography predicts long-term survival following pneumonectomy for lung cancer. Interact Cardiovasc Thorac Surg. 2019;28(4):542-549. https://doi.org/10.1093/icvts/ivy280
14. Fintelmann FJ, Troschel FM, Mario J, et al. Thoracic skeletal muscle is associated with adverse outcomes after lobectomy for lung cancer. Ann Thorac Surg. 2018;105(5):1507-1515. https://doi.org/10.1016/j.athoracsur.2018.01.013
15. Madariaga MLL, Troschel FM, Best TD, Knoll SJ, Gaißert HA, Fintelmann FJ. Low thoracic skeletal muscle area predicts morbidity after pneumonectomy for lung cancer. Ann Thorac Surg. 2020;109(3):907-913. https://doi.org/10.1016/j.athoracsur.2019.10.041
16. Best TD, Mercaldo SF, Bryan DS, et al. Multilevel body composition analysis on chest computed tomography predicts hospital length of stay and complications after lobectomy for lung cancer. Ann Surg. 2020;Publish Ah(Xx). https://doi.org/10.1097/SLA.0000000000004040
17. McDonald AM, Swain TA, Mayhew DL, et al. CT measures of bone mineral density and muscle mass can be used to predict noncancer death in men with prostate cancer. Radiology.
18. Lee JS-J, He K, Harbaugh CM, et al. Frailty, core muscle size, and mortality in patients undergoing open abdominal aortic aneurysm repair. J Vasc Surg. 2011;53(4):912-917. https://doi.org/10.1016/j.jvs.2010.10.111

19. Birim Ö, Maat APWM, Kappetein AP, Van Meerbeeck JP, Damhuis RAM, Bogers AJJC. Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer. Eur J Cardio-thoracic Surg. 2003;23(1):30-34. https://doi.org/10.1016/S1010-7940(02)00721-2

20. Mason DP, Subramanian S, Nowicki ER, et al. Impact of smoking cessation before resection of lung cancer: a society of thoracic surgeons general thoracic surgery database study. Ann Thorac Surg. 2009;88(2):362-371. https://doi.org/10.1016/j.athoracsur.2009.04.035

21. Fernandez FG, Force SD, Pickens A, Kilgo PD, Luu T, Miller DL. Impact of laterality on early and late survival after pneumonectomy. Ann Thorac Surg. 2011;92(1):244-249. https://doi.org/10.1016/j.athoracsur.2011.03.021

22. Brunelli A, Ciconi S, Decaluwe H, Sonto Z, Falcoz PE. Parsimonious Euvolung risk models to predict cardiopulmonary morbidity and mortality following anatomic lung resections: An updated analysis from the European Society of Thoracic Surgeons database. Eur J Cardio-thoracic Surg. 2020;57(3):455-461. https://doi.org/10.1093/ejcts/ezz272

23. Troschel AS, Troschel FM, Muniappan A, Gaissert HA, Fintelmann FJ. Role of skeletal muscle on chest computed tomography for risk stratification of lung cancer patients. J Thorac Dis. 2019;11(3):S483-S484. doi:https://doi.org/10.21037/jtd.2019.01.73.

24. Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58-67. https://doi.org/10.1016/j.ejca.2015.12.030

25. Putsuka SP, Boorjjan SA, Moynagh MR, et al. Decreased skeletal muscle mass is associated with an increased risk of mortality after radical nephrectomy for localized renal cell cancer. J Urol. 2016;195(2):270-276. https://doi.org/10.1016/j.juro.2015.08.072

26. Sueda T, Takahasi H, Nishimura J, et al. Impact of low muscularity and myosteatosis on long-term outcome after curative colorectal cancer surgery: a propensity score-matched analysis. Dis Colon Rectum. 2018;61(3):364-374. https://doi.org/10.1097/DCR.0000000000001958

27. Putsuka SP, Carrasco A, Schmit GD, et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer. 2014;120(18):2910-2918. https://doi.org/10.1002/cncr.28798

28. Higgins MJ, Martini DJ, Patil DH, et al. Sarcopenia and modified Glasgow prognostic score predict post-surgical outcomes in localized renal cell carcinoma. Cancer. 2021;127(12):1974-1983. https://doi.org/10.1002/cncr.33462

29. Ferguson MK, Mitzman B, Derstine B, et al. A Morphomic index is an independent predictor of survival after lung cancer resection. Ann Thorac Surg. 2020;109(3):873-878. https://doi.org/10.1016/j.athoracsur.2019.10.064

30. Borri A, Leo F, Veronesi G, et al. Extended pneumonectomy for non-small cell lung cancer: Morbidity, mortality, and long-term results. J Thorac Cardiovasc Surg. 2007;134(5):1266-1272. https://doi.org/10.1016/j.jtcvs.2007.01.021

31. Tabutin M, Couraud S, Guibert B, Mulsant P, Souquet PJ, Trone F. Completion pneumonectomy in patients with cancer: postoperative survival and mortality factors. J Thorac Oncol. 2012;7(10):1556-1562. https://doi.org/10.1097/JTO.0b013e3186419d2

32. d’Amato TA, Ashrafi AS, Schuchert MJ, et al. Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg. 2009;88(4):1079-1085. https://doi.org/10.1016/j.athoracsur.2009.06.025

33. Gaissert HA, Keum DY, Wright CD, et al. POINT: operative risk of pneumonectomy-Influence of preoperative induction therapy. J Thorac Cardiovasc Surg. 2009;138(2):289-294. https://doi.org/10.1016/j.jtcvs.2008.11.069

34. Englesbe MJ, Terjimanian MN, Lee JS, et al. Morphometric age and surgical risk. J Am Coll Surg. 2013;216(5):976-985. https://doi.org/10.1016/j.jamcollsurg.2013.01.052

35. Magudia K, Bridge C, Bay C, et al. Population-scale CT-based body composition analysis of a large, previously healthy outpatient population using deep learning to derive age, gender and race specific reference curves. Radiology. 2020;298(2):319-329.

36. Nattenmüler J, Wochner R, Muley T, et al. Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients. PLoS One. 2017;12(1):1-18. https://doi.org/10.1371/journal.pone.0169136

37. Williams GR, Al-Obaidi M, Dai C, Bhatia S, Giri S. SARC-F for screening of sarcopenia among older adults with cancer. Cancer. 2020;127(9):1469-1475. https://doi.org/10.1002/cncr.33395

38. Stokes SM, Massarweh NN, Stringham JR, Varghese TK. Clinical-pathologic correlation and guideline concordance in resectable non-small cell lung cancer. Ann Thorac Surg. 2019;108(3):837-844. https://doi.org/10.1016/j.athoracsur.2019.03.062

39. Kumar S, Khosravi M, Massart A, Polluri M, Davenport A. The effects of racial differences on body composition and total body water measured by multifrequency bioelectrical impedance analysis influence delivered Kt/V dialysis dosing. Nephron Clin Pract. 2013;124(1–2):60-66. https://doi.org/10.1159/000355009

40. Schabath MB, Cress WD, Muñoz-Antonio T. Racial and ethnic differences in the epidemiology and genomics of lung cancer. Cancer Control. 2016;23(4):338-346. https://doi.org/10.1177/107327481602300405

**SUPPORTING INFORMATION**

Additional supporting information may be found online in the Supporting Information section.